AMPYRA (dalfampridine) 2014 Net Sales Guidance of $328-$335 Million

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that AMPYRA(R) (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2013 were $84 million, and unaudited AMPYRA 2013 full-year net sales were $302 million. These results are preliminary and subject to completion of the Company's year-end audit.
READ MORE